Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 3.6% – Time to Sell?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) shares fell 3.6% during trading on Tuesday . The company traded as low as $3.18 and last traded at $3.18. 11,656 shares were traded during trading, a decline of 99% from the average session volume of 1,278,503 shares. The stock had previously closed at $3.30.

Cyclerion Therapeutics Stock Performance

The business’s 50-day moving average price is $3.13 and its 200 day moving average price is $3.01. The stock has a market capitalization of $10.21 million, a PE ratio of -2.74 and a beta of 1.55.

Hedge Funds Weigh In On Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Renaissance Technologies LLC acquired a new position in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,611 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned 0.39% of Cyclerion Therapeutics as of its most recent filing with the Securities & Exchange Commission. 75.62% of the stock is owned by institutional investors.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.